Healthcare Intelligence
Pharma Drug Discovery & R&D
Real-time intelligence, expert analysis, and verified research for the Pharma Drug Discovery & R&D industry. Stay ahead in 3 minutes a day.
Stay ahead of Pharma Drug Discovery & R&D in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
CRISPR Sickle Cell Therapy Approved for Children as Young as Two
FDA expands Casgevy approval to ages 2+, making it the first CRISPR therapy available to 5,500 additional children with sickle cell disease.
Read full articleAnthropic Launches Own Drug Discovery Programs for Neglected Diseases
AI company will develop treatments for unprofitable diseases while building better models through firsthand pharma experience.
Read full articleTakeda Signs $600M AI Drug Discovery Deal with Insilico Medicine
Partnership leverages Insilico's Pharma.AI platform for next-gen therapeutics, with $60M upfront and up to $600M in milestones.
Read full articleAnthropic Unveils Claude Science AI Workbench for Researchers
New platform integrates fragmented tools and datasets, with UCSF researcher using it to spot viral contamination missed for a year.
Read full articleNovartis CEO: AI Could Cut Drug Development Time to 7-8 Years
AI models may reduce 12-year timelines by 40% and double success rates from 8% to 16% through better safety predictions.
Read full articleFDA Fast-Tracks CRISPR Therapy Review Under Priority Voucher Program
Casgevy pediatric expansion approved in just 53 days vs standard 6+ months, marking eighth therapy under Commissioner's pilot program.
Read full article100% Success Rate in Pediatric CRISPR Sickle Cell Trial
All 8 evaluable children achieved freedom from severe pain crises for 12+ months; beta-thalassemia trial shows 89% transfusion independence.
Read full articleBig Pharma Spends $150-200B Yearly on R&D for Just 800-1000 Drugs
Novartis CEO highlights inefficiency: major pharma produced only 800-1000 drugs in 120 years despite massive annual R&D investment.
Read full articleCRISPR Sickle Cell Therapy Approved for Children as Young as Two
FDA expands Casgevy approval to ages 2+, making it the first CRISPR therapy available to 5,500 additional children with sickle cell disease.
Read full articleAnthropic Launches Own Drug Discovery Programs for Neglected Diseases
AI company will develop treatments for unprofitable diseases while building better models through firsthand pharma experience.
Read full articleTakeda Signs $600M AI Drug Discovery Deal with Insilico Medicine
Partnership leverages Insilico's Pharma.AI platform for next-gen therapeutics, with $60M upfront and up to $600M in milestones.
Read full articleAnthropic Unveils Claude Science AI Workbench for Researchers
New platform integrates fragmented tools and datasets, with UCSF researcher using it to spot viral contamination missed for a year.
Read full articleNovartis CEO: AI Could Cut Drug Development Time to 7-8 Years
AI models may reduce 12-year timelines by 40% and double success rates from 8% to 16% through better safety predictions.
Read full articleFDA Fast-Tracks CRISPR Therapy Review Under Priority Voucher Program
Casgevy pediatric expansion approved in just 53 days vs standard 6+ months, marking eighth therapy under Commissioner's pilot program.
Read full article100% Success Rate in Pediatric CRISPR Sickle Cell Trial
All 8 evaluable children achieved freedom from severe pain crises for 12+ months; beta-thalassemia trial shows 89% transfusion independence.
Read full articleBig Pharma Spends $150-200B Yearly on R&D for Just 800-1000 Drugs
Novartis CEO highlights inefficiency: major pharma produced only 800-1000 drugs in 120 years despite massive annual R&D investment.
Read full articleStay ahead of Pharma Drug Discovery & R&D in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.